The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be celebrating a first-in-class approval from the FDA for Wegovy in metabolic dysfunction-associated steatohepatitis (MASH).